Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ037130 in Advanced Solid Tumors
NCT07715747Phase 1Recruiting
- Sponsor
- TJ Biopharma
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TJ037130 in solid tumor, ovarian cancer, gastric cancer (GC) and 1 more, sponsored by TJ Biopharma. Primary endpoint: Adverse Events at 90 days. Started Aug 2026; status: recruiting.
02
Drugs
TJ037130
03
Conditions
solid tumorovarian cancergastric cancer (GC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07715747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715747.